Combining molecular imaging and fluid biomarkers to unlock insights into Parkinson’s disease
The integration of molecular imaging and fluid biomarkers is crucial for understanding and diagnosing Parkinson's disease. Early detection of pathology is emphasized, along with the role of biomarkers in neurodegenerative diseases. Differences between Parkinson's and other Lewy body diseases are discussed, highlighting cognitive decline and the potential of new biomarkers. Challenges in clinical implementation and the need for collaboration between the pharmaceutical industry and imaging vendors are also addressed.Speaker: Thilo van Eimeren
Level: Advanced
Topics in this course:
